{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"49.7","spread":"49.7","upperLimit":"76.8","value":"64.1"},{"groupId":"OG001","lowerLimit":"62.1","spread":"62.1","upperLimit":"86.1","value":"75.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"39"},{"groupId":"OG001","value":"41"}],"units":"Participants"}],"description":"ORR was defined as the percentage of participants who achieved partial response (PR) or better responses based on the computerized algorithm, in accordance with the IMWG criteria, during or after the study treatment but before the start of subsequent anti-myeloma therapy. IMWG criteria for PR: greater than or equal to (\\>=)50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by \\>=90% or less than (\\<)200 mg/24 hours; If the serum and urine M-protein were not measurable, a decrease of \\>=50% in the difference between involved and uninvolved free light chain (FLC) levels was required in place of the M-protein criteria; If serum and urine M-protein were not measurable, and serum free light assay is also not measurable, \\>=50% reduction in bone marrow plasma cells (PCs) was required in place of M-protein, provided baseline bone marrow plasma cell percentage was \\>=30%; additionally, if present at baseline, \\>=50% reduction in the size of soft tissue PCs was also required.","dispersionType":"90% Confidence Interval","groups":[{"description":"Participants received carfilzomib 20 milligram per meter square (mg/m\\^2) intravenously (IV) on Cycle 1 Day 1 and then 70 mg/m\\^2 on Cycle 1 Days 8 and 15, and thereafter on Days 1, 8, 15 from Cycle 2 onwards. Participants received dexamethasone 20 milligrams (mg) on Cycle 1 Days 1 and 2, and 40 mg IV or orally on Days 8, 15, 22 of Cycle 1. Participants then received dexamethasone 40 mg IV or orally on Days 1, 8, 15 and 22 of Cycles 2-9, then on Days 1, 8, 15 from Cycle 10 onwards, until confirmed progressive disease (PD), death, intolerable toxicity, start of a new treatment for multiple myeloma, withdrawal of consent, or end of the study, whichever occurs first. Each cycle of 28 days.","id":"OG000","title":"Arm A: Carfilzomib+Dexamethasone (Kd)"},{"description":"Participants received daratumumab 1800 mg by SC injection (Dara-SC) on Days 1, 8, 15, 22 of Cycle 1 and 2, Days 1 and 15 of Cycle 3-6, and on Day 1 from Cycle 7 onwards. Participants received carfilzomib 20 mg/m\\^2 IV on Cycle 1 Day 1 and then 70 mg/m\\^2 on Cycle 1 Days 8 and 15, and Days 1, 8 and 15 from Cycle 2 onwards. Participants received dexamethasone 20 mg on Cycle 1 Days 1 and 2 and 40 mg IV or orally on Days 8, 15, 22 of Cycle 1. Participants then received dexamethasone 40 mg IV or orally on Days 1, 8, 15 and 22 of Cycles 2-9, then on Days 1, 8, 15 from Cycle 10 onwards, until confirmed PD, death, intolerable toxicity, start of a new treatment for multiple myeloma, withdrawal of consent, or end of the study, whichever occurs first. Each cycle of 28 days.","id":"OG001","title":"Arm B: Dara-SC in Combination With Kd (DKd)"}],"paramType":"NUMBER","populationDescription":"The response-evaluable analysis set included participants who had confirmed diagnosis of multiple myeloma and measurable disease at baseline or screening visit.","reportingStatus":"POSTED","timeFrame":"Up to 3 years and 7 months","title":"Overall Response Rate (ORR)","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}